Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 39,3 M
EBIT 2015 -2,71 M
Net income 2015 -6,28 M
Finance 2015 29,7 M
Yield 2015 -
Sales 2016 65,0 M
EBIT 2016 8,88 M
Net income 2016 -1,22 M
Finance 2016 0,20 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 9,53x
EV / Sales 2016 6,22x
Capitalization 404 M
More Financials
Company
IGI Laboratories, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
08/10 IGI LABORATORIES : Technical Report on Biotechnology Stocks -- Immunomedics, Ver..
07/23 IGI LABORATORIES : Announces Second Quarter 2015 Results
07/23 IGI LABORATORIES : Announces Sixth ANDA Submission Of 2015
07/09 IGI LABORATORIES : To Hold Conference Call For 2nd Quarter 2015 Results
07/09 IGI LABORATORIES : Announces FDA Approval And Commercial Launch Of Diclofenac So..
06/30 IGI LABORATORIES : Announces Fifth ANDA Submission Of 2015
06/09 IGI LABORATORIES : Announces Fourth ANDA Submission of 2015
05/28 IGI LABORATORIES : Announces Third ANDA Submission Of 2015
More news
Sector news : Pharmaceuticals - NEC
03:46pDJFDA : Some Diabetes Drugs Can Cause Joint Pain
03:37p PERRIGO : BRIEF: Mylan shareholders approve Perrigo takeover bid
03:35pDJFDA Says Certain Type 2 Diabetes Drugs Can Cause Serious Joint Pain -- Update
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions